While the speed of science is both lauded and mistrusted by near-equal parts of the population, the over 22 million Americans with cancer are now saying, “Wait, what about us?”

The burgeoning genetic capabilities were instrumental in causing Semigran to transition into the biotech industry.

Teva announced the appointment in a filing with the U.S. Securities and Exchange Commission. Zaks will serve on the board’s Science and Technology Committee.

As CEO, Stolpe has presided over some highs with the launch of JAK1 inhibitor Jyseleca (filgotinib) in Europe, as well as the devaluation of the company's share price by 70%.

​The trial will enroll about 4,000 people worldwide to confirm the drug's safety and immunogenicity profiles.

AC Immune and Genentech announced that their Phase II Lauriet trial of semorinemab in mild-to-moderate Alzheimer’s disease hit one of its co-primary endpoints.

The state-of-the-art 146,000 square foot facility will make it easier for Umoja to eliminate crucial CAR-T production barriers.

The research underlines the progress being made in messenger RNA approaches, as spotlighted by the success of the mRNA vaccines against COVID-19.

​SpringWorks has announced a research collaboration with the Dana-Farber Cancer Institute to advance its therapy development efforts for multiple myeloma and related diseases.

Two former executives of JHL Biotech were indicted on charges of orchestrating the theft of trade secrets, wire fraud exceeding $101 million, and money laundering.

​Laronde has managed to secure as much as $440 million from a Series B financing round to support as many as 100 Endless RNA (eRNA) products and drug programs over the next decade.

Regeneron and Sanofi broke ground with the 2017 approval of the first biologic drug for atopic dermatitis, the most common form of eczema driven by allergic reactions.

Shares of Bone Therapeutics are down more than 34% on the Euronext stock exchange after the company announced its Phase III osteoarthritis study failed to meet primary and critical secondary endpoints.

A new variant, C.1.2. is causing public health experts worldwide to keep an eye out for its presence as it seems to be more infectious and even more resistant to vaccines than other variants.

The SPAC craze continues as San Diego-based Revelation Biosciences announced its merger with Petra Acquisition that will result in the company’s listing on the Nasdaq exchange.

It was a busy week for clinical trial news. Here’s a look.